Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million in a series B round Wednesday led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of its second most advanced candidate, CBP-201, to treat atopic dermatitis.

Connect's lead product, CBP-307, is in two Phase II trials to treat ulcerative colitis and Crohn's disease. CBP-307 is a second-generation S1PR1 agonist and CBP-201 is a mAb against IL-4R...